We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Mast-Cell Stabilizing Effects of Olopatadine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00389025
Recruitment Status : Completed
First Posted : October 17, 2006
Last Update Posted : November 22, 2016
Information provided by:
Alcon Research

Brief Summary:
To assess the effects of olopatadine of the release of mast cell histamine

Condition or disease Intervention/treatment Phase
Allergic Conjunctivitis Drug: Olopatadine (generic name) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Mast-Cell Stabilizing Effects of Olopatadine
Study Start Date : October 2006
Primary Completion Date : April 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pinkeye
U.S. FDA Resources

Primary Outcome Measures :
  1. Tear histamine

Secondary Outcome Measures :
  1. Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Asymptomatic and not using any topical or systemic medication

Exclusion Criteria:

  • Age

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00389025

Padova Site
Padova, Italy
Sponsors and Collaborators
Alcon Research
Study Director: Terry Wiernas Alcon Research

Additional Information:
ClinicalTrials.gov Identifier: NCT00389025     History of Changes
Other Study ID Numbers: C-05-30
First Posted: October 17, 2006    Key Record Dates
Last Update Posted: November 22, 2016
Last Verified: January 2010

Keywords provided by Alcon Research:
Subject with clinical history of seasonal allergic conjunctivitis

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases
Olopatadine Hydrochloride
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action